Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

B. Rossetti, R. Gagliardini, G. Meini, G. Sterrantino, V. Colangeli, M.C. Re, A. Latini, M. Colafigli, F. Vignale, S. Rusconi, V. Micheli, A.D. Biagio, G. Orofino, V. Ghisetti, A. Fantauzzi, V. Vullo, P. Grima, D. Francisci, C. Mastroianni, A. AntinoriM. Trezzi, L. Lisi, P. Navarra, B. Canovari, A. D’Arminio Monforte, S. Lamonica, A. D’Avino, M. Zazzi, S.D. Giambenedetto, A. De Luca

Research output: Contribution to journalArticle

Original languageEnglish
Article numbere0187393
Number of pages18
JournalPLoS One
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 21 2017

Cite this

Rossetti, B., Gagliardini, R., Meini, G., Sterrantino, G., Colangeli, V., Re, M. C., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Micheli, V., Biagio, A. D., Orofino, G., Ghisetti, V., Fantauzzi, A., Vullo, V., Grima, P., Francisci, D., Mastroianni, C., ... De Luca, A. (2017). Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial. PLoS One, 12(11), [e0187393]. https://doi.org/10.1371/journal.pone.0187393